SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr Reddy's Lab launches OTC store-brand equivalent of Mucinex D Extended Release Tablets

09 Jul 2019 Evaluate

Dr. Reddy's Laboratories has launched an over-the-counter (OTC) store-brand equivalent of Mucinex D Extended Release Tablets in two strengths-Guaifenesin 600 mg and Pseudoephedrine HCI 60 mg, and Guaifenesin 1200 mg and Pseudoephedrine HCI 120 mg-in the United States market, as approved by the US Food and Drug Administration (USFDA).

The company’s OTC Guaifenesin and Pseudoephedrine HCI is used to help loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive; temporarily relieve nasal congestion due to common cold, hay fever, and upper respiratory allergies; temporarily restore freer breathing through the nose; promote nasal and/or sinus drainage; and temporarily relieve sinus congestion and pressure.

According to IRI, the Mucinex D brand and store brands had combined US sales of around $71 million MAT for the most recent twelve months ending in May 2019. The company’s OTC Guaifenesin 1200 mg and Pseudoephedrine HCI 120 mg is available in 24-count packages. Also, the company’s OTC Guaifenesin 600 mg and Pseudoephedrine HCI 60 mg is available in 18 and 36-count packages. 

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1220.00 -12.25 (-0.99%)
21-Apr-2026 15:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.70
Dr. Reddys Lab 1220.00
Cipla 1232.60
Zydus Lifesciences 928.05
Lupin 2305.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×